Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Riess

Showing results (41-50 of 132) with videos related to

Pageof 14
Sort By:
Npj Metabolic Health and Disease|May 27, 2024
Potential roles of sex-linked differences in obesity and cancer immunotherapy: revisiting the obesity paradoxLogan V Vick, Spencer Rosario, Jonathan W Riess, et al.
Clinical Lung Cancer|November 2, 2013
Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implicationsDavid R Gandara, Tianhong Li, Primo N Lara, et al.
Translational Lung Cancer Research|October 24, 2025
Actionable mutations and targeted therapy in non-small cell lung cancer among Latin American and Hispanic patients: a systematic literature review of prognosis and meta-analysisJuan Pablo Castañeda-González, Jonathan W Riess, María Paula Gómez-Gómez, et al.
Clinical Lung Cancer|February 15, 2014
Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment eraJonathan W Riess, Seema Nagpal, Michael Iv, et al.
Clinical Lung Cancer|February 19, 2019
Increased Galectin-1 Expression in Thymic Epithelial TumorsJonathan W Riess, Christina S Kong, Robert B West, et al.
Clinical Lung Cancer|July 2, 2013
A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangementsJonathan W Riess, Sukhmani K Padda, Charles D Bangs, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 18, 2014
Diffuse high intensity PD-L1 staining in thymic epithelial tumorsSukhmani K Padda, Jonathan W Riess, Erich J Schwartz, et al.
The Oncologist|September 8, 2023
Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic ProfilesAndreas M Heilmann, Jonathan W Riess, Margaret McLaughlin-Drubin, et al.
Clinical Lung Cancer|February 2, 2025
POLE Mutation Associated With Microsatellite Instability and High Tumor Mutational Burden Confers Exquisite Sensitivity to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer: A Case Report and Genomic Database AnalysisMatthew S Lara, Jonathan W Riess, Guneet Kaleka, et al.
Cancer Chemotherapy and Pharmacology|May 16, 2021
Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumorsThomas J Semrad, Edward J Kim, I-Yeh Gong, et al.
Pageof 14

Showing results (41-50 of 132) with videos related to

Sort By:
Pageof 14
Npj Metabolic Health and Disease|May 27, 2024
Potential roles of sex-linked differences in obesity and cancer immunotherapy: revisiting the obesity paradoxLogan V Vick, Spencer Rosario, Jonathan W Riess, et al.
Clinical Lung Cancer|November 2, 2013
Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implicationsDavid R Gandara, Tianhong Li, Primo N Lara, et al.
Translational Lung Cancer Research|October 24, 2025
Actionable mutations and targeted therapy in non-small cell lung cancer among Latin American and Hispanic patients: a systematic literature review of prognosis and meta-analysisJuan Pablo Castañeda-González, Jonathan W Riess, María Paula Gómez-Gómez, et al.
Clinical Lung Cancer|February 15, 2014
Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment eraJonathan W Riess, Seema Nagpal, Michael Iv, et al.
Clinical Lung Cancer|February 19, 2019
Increased Galectin-1 Expression in Thymic Epithelial TumorsJonathan W Riess, Christina S Kong, Robert B West, et al.
Clinical Lung Cancer|July 2, 2013
A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangementsJonathan W Riess, Sukhmani K Padda, Charles D Bangs, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 18, 2014
Diffuse high intensity PD-L1 staining in thymic epithelial tumorsSukhmani K Padda, Jonathan W Riess, Erich J Schwartz, et al.
The Oncologist|September 8, 2023
Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic ProfilesAndreas M Heilmann, Jonathan W Riess, Margaret McLaughlin-Drubin, et al.
Clinical Lung Cancer|February 2, 2025
POLE Mutation Associated With Microsatellite Instability and High Tumor Mutational Burden Confers Exquisite Sensitivity to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer: A Case Report and Genomic Database AnalysisMatthew S Lara, Jonathan W Riess, Guneet Kaleka, et al.
Cancer Chemotherapy and Pharmacology|May 16, 2021
Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumorsThomas J Semrad, Edward J Kim, I-Yeh Gong, et al.
Pageof 14